Hypoglycemia: From the Laboratory to the Clinic by Amiel, Stephanie A.
Hypoglycemia: From the Laboratory to the
Clinic
H
ypoglycemia is the major, and most
feared, complication of the phar-
macological therapies for diabetes.
In health, hypoglycemia sufﬁcient to
cause clinically relevant impairment of
cognitive function or cardiac rhythm is
preventedbyhighlyefﬁcientcounterregu-
latory mechanisms that culminate in resto-
rationofcirculatingglucoseconcentrations.
In the accompanying article, McCrimmon
(1) has summarized our current under-
standing of how these mechanisms may be
initiatedandcoordinatedbycentralglucose
sensing, described the possible molecular
mechanisms of neuronal glucose sensing,
and alluded to the defective performance of
these mechanisms in insulin-treated
diabetes.
The principle clinical correlate of de-
fectivebrainglucosesensingindiabetesis
the change in the patient’s awareness of
the plasma glucose concentration. The
clinical phenomenon of loss of awareness
of hypoglycemia, and its associated in-
crease in risk of severe hypoglycemia, is
accompanied by measurable defects in
the counterregulatory stress responses at-
tributedatleastinparttofailureofcentral
glucose sensing. As McCrimmon ex-
plains, the main determinant of the
plasma glucose concentrations at which
the brain responds actively to hypoglyce-
mia appears to be the recent antecedent
glucose exposure. Thus, people accus-
tomed to chronic hyperglycemia may ac-
tivatesymptomaticstressresponsesasthe
glucose concentration falls within the
physiological range—a barrier for some
to tighten glucose control effectively.
Moreextensivelyexploredisthephenom-
enon of hypoglycemia unawareness, in
which the body only mounts a protective
counterregulatory response to falling
blood glucose at glucose concentrations
well below the physiologic norm. Added
to the failure of glucagon responses to hy-
poglycemia that occurs early in type 1 di-
abetes, such additional counterregulatory
failure may leave the patient symptom
free and defenseless until plasma glucose
concentrations are insufﬁcient to support
normal higher brain function. Confusion
becomes the ﬁrst sign of the hypoglyce-
mia, and severe episodes (those in which
the person is rendered incapable of self-
treatment) ensue. In this article, we will
look at the insights clinical research has
provided into such hypoglycemia un-
awareness, how the clinical and labora-
tory research data have inﬂuenced our
understanding and management of prob-
lematic hypoglycemia in those with dia-
betes, and the implications of the basic
science for future diabetes management.
Hypoglycemia unawareness
Hypoglycemia unawareness and its asso-
ciated increase in risk of severe hypogly-
cemia came to prominence with the
publication of the three-fold increase in
severe hypoglycemia seen in the inten-
sively treated arm of the Diabetes Control
and Complications Trial (DCCT). In that
randomized controlled trial of intensive
versus what was then conventional insu-
lin therapy, severe hypoglycemia was not
only more common in a curvilinear fash-
ion with lower glycated hemoglobin, but
therewasalsoasigniﬁcantlyhigherriskin
the intensively treated group at any given
achieved glycated hemoglobin (2). Such
data have given rise to the perception that
hypoglycemia unawareness and high risk
of severe hypoglycemia are inextricably
linked to tight glycemic control. In fact,
this is not the case. Some people with di-
abetes and consistently high glycated he-
moglobincanexperiencerecurrentsevere
hypoglycemia. People who choose to set
their glucose targets high to diminish risk
of severe hypoglycemia do not always
achieve their aim. Contemporaneously
with the DCCT, the Du ¨sseldorf program
of structured education for people with
type1diabeteswasconsistentlyachieving
reductions in glycated hemoglobin with
signiﬁcantlyreducedratesofseverehypo-
glycemia (3), perhaps the best deﬁnition
of good glycemic control that we have.
Although many studies ﬁnd an inverse
correlation between glycated hemoglobin
and rate of severe hypoglycemia, this is
not always the case. Table 1 lists factors
associated with increased risk of severe
hypoglycemia in clinical practice. One of
the best predictors is an absence of C-
peptide; another even stronger predictor
ishavingahistoryofseverehypoglycemia
(4).Inthosewithtype2diabetes,increas-
ing age and the presence of comorbidities
are proven additional risk factors, which
may be relevant to those with all types of
diabetes (5).
Loss of endogenous insulin and
hypoglycemia risk
Lack of C-peptide indicates a complete
deﬁciency of endogenous insulin. Its as-
sociation with increased risk of severe hy-
poglycemia may relate to the loss of
capacity for even vestigial reduction of an
endogenous insulin response to hypogly-
cemia. In support of this, islet transplan-
tation can restore protection from severe
hypoglycemia even when the patient re-
mains insulin requiring and on exoge-
nous insulin, despite apparently not
restoringglucagonresponsestothefalling
glucose (6). Persistence of insulin effect
has long been known to impair counter-
regulation and was considered to be the
mechanism of increased risk of severe hy-
poglycemia posed by high levels of in-
sulin antibodies in the days before
monocomponent and human insulins
(7). Loss of the cessation of endogenous
insulin secretion as a paracrine signal to
the -cell to release glucagon may be an-
other important contributory factor that
makes total loss of all endogenous insulin
secretion a high risk for severe hypogly-
cemia. Certainly, maintaining intraislet
insulin with a sulfonylurea during hypo-
glycemia markedly attenuates the gluca-
gon response (8). Amylin, which in
healthy subjects is cosecreted with insu-
lin,doesnotappeartoaffectcounterregu-
lation (9), although it may smooth out
glucose proﬁles in subjects with type 1
diabetes (10). The evidence suggests that
glucagon responses are lost in those with
type1diabeteswithintheﬁrst5yearsand
that at least in some people, catechol-
amine responses are also diminished over
a longer diabetes duration (7). In those
with type 2 diabetes, the glucagon deﬁcit
appears to develop in parallel with defec-
tive responses of endogenous insulin
(11). Whereas no therapeutic maneuvers
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can restore glucagon responses to hypo-
glycemia in those with type 1 diabetes,
some restoration of other defects can be
made based on our current understand-
ing of how they arise.
The role of antecedent hypoglycemia
The link between defective glucose coun-
terregulation and high risk of severe hy-
poglycemia is not only intuitive, it has
been well demonstrated experimentally.
Ryder et al. (12) showed that failure to
arrest a glucose fall during an unopposed
insulin infusion was associated with fail-
ure of the counterregulatory hormone
response to the hypoglycemia (and
incidentally had no causal relationship
withdiabeticautonomicneuropathy)and
also with clinical problems with severe
hypoglycemia. White et al. (13) used fail-
ure to counterregulate during insulin in-
fusion as a successful predictor of future
problematic hypoglycemia in subsequent
application of intensiﬁed insulin therapy.
Although it was initially hoped that im-
proved glycemic control might enhance
counterregulation, perhaps restoring de-
fective glucagon responses to hypoglyce-
mia, this did not occur. Indeed, the early
methodsofinsulinintensiﬁcation,suchas
thoseusedinDCCT,wereassociatedwith
increasing counterregulatory failure. De-
fective counterregulation appeared to be
induced by the tightened glucose control
(see Fig. 1) (14,15).
A seminal study showed that the glu-
cose concentration required to induce se-
cretion of catecholamines in hypoglycemia
could be lowered in healthy volunteers by
prior exposure to two episodes of experi-
mental hypoglycemia the preceding day
(16). This work has since been repeated in
people with type 1 and type 2 diabetes and
appears consistent. There is some dispute
about the degree of antecedent hypoglyce-
miarequiredtoinducetheproblem.Exper-
imentalreductionofarterialplasmaglucose
to only 3.9 mmol/l induces defects primar-
ily in the glucagon responses to subsequent
hypoglycemia, but this response is of little
relevancetotheinsulin-deﬁcientpatient,al-
though increases in epinephrine and mus-
cle sympathetic nerve activity were also
reduced(17).Reductionsinplasmaglucose
to just below the physiological range (3.3
mmol/l) have more extreme effects on the
catecholamine, pancreatic polypeptide,
growthhormone,endogenousglucosepro-
duction,andlipolyticresponsestohypogly-
cemia, although at least 30 min of exposure
to lower glucose concentrations is required
to affect subjective awareness, at least in ex-
perimental models (18). In type 2 diabetes,
a recent study has shown reduction of ex-
aggerated counterregulatory hormone re-
sponses by improved glycemic control,
with a further defect inducible by a single
experimental exposure to a plasma glucose
of 3.3 mmol/l (19).
Perhaps of greater clinical relevance
has been the demonstration that aware-
ness could be restored to the hypoglyce-
miaunawarebyavoidanceofallexposure
to a plasma glucose of 3 mmol/l. This
was demonstrated not just in people with
short duration diabetes and tight control
but also in people with long duration di-
abetes, both using and far from using in-
tensiﬁed therapy regimens (20). It is of
interest to note that whereas most studies
showed at least some restoration of both
counterregulatory hormone responses to
hypoglycemia as well as restoration of
subjective awareness, one study showed
recovery of awareness alone without any
impact on defective catecholamine re-
sponses (21). This dissociation between
the counterregulatory hormone re-
sponses and subjective awareness is ex-
plored below.
Cortical activation in hypoglycemia
perception
McCrimmon rightly focuses his paper
on current research on the molecular
mechanisms of glucose sensing in the
brain centers that respond to a change
in glucose supply with a change in ac-
tion potential brain regions such as the
nuclei of the hypothalamus (1). These
neuronsarecriticalsensorsandcoordina-
tors of the counterregulatory response.
However, subjective awareness of hypo-
glycemia and the ability to respond to
such awareness by taking on carbohy-
dratesisthediabeticpatient’sbestdefense
against severe hypoglycemia. Whereas
the mechanisms that drive symptomatic
counterregulatory responses may have
originsinmanybrainregions,thepercep-
tion of symptoms is clearly a cortical
activity.
Neuroimaging studies in human
subjects have consistently failed to
show an increase in brain glucose up-
take at euglycemia or hypoglycemia in
those accustomed to hypoglycemia who
are hypoglycemia unaware. This is in
contrast to studies showing upregulation
of glucose transporters in animal models
of antecedent hypoglycemia experience
and two human studies estimating global
brain glucose uptake from cross-brain ar-
Table 1—Contributors to increased risk of severe hypoglycemia
1. Loss of endogenous insulin secretion
a. Inability to reduce circulating insulin concentrations
b. Loss of signal to -cells to increase glucagon secretion
c. Possible loss of C-peptide or amylin effects
2. Primary failure of hormones raising blood glucose concentrations
a .Hypopituitarism
b. Adrenal cortical failure
c. Isolated growth hormone deﬁciency
3. Defective glucose counterregulation
a. Loss of glucagon response to hypoglycaemia (see 1b)
b. Delayed onset of counterregulatory response secondary to antecedent hypoglycemia
experience
4. Prolongation of insulin effect
a. Exogenous insulin injection
b. Insulin secretagogues
c. Renal impairment
d. Hypothyroidism
e. Liver failure
f. High levels of insulin-binding antibodies
g. Rare activating insulin receptor autoantibodies
5. Exaggerated mismatch between insulin and nutrient absorption
a. Primary gastrointestinal disease with malabsorption, e.g., celiac disease
b. Delayed insulin administration
6. Lifestyle contributors to individual episodes of severe hypoglycemia
a. Acute increase in muscle glucose uptake during exercise
b. Depletion of liver and muscle glycogen by vigorous/prolonged exercise
c. Suppression of gluconeogenesis by alcohol
d. Use of drugs enhancing effects of insulin secretagogues
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ter prolonged or recurrent hypoglycemia.
Importantly, human global brain imaging
does show cortical as well as brain stem
activation during hypoglycemia. Teves et
al. (22) showed an increase in regional
brain perfusion using [15O]-H2O water
positron emission tomography (PET) in
anterior cingulate cortex and thalamus
during hypoglycemia in healthy volun-
teers. Although primary changes in cere-
bral blood ﬂow do not directly alter rates
of cerebral metabolism, changes in re-
gional brain perfusion detected by water
PET are thought to be driven by regional
changes in neuronal activation and their
associated regional changes in cerebral
metabolism and thus form a surrogate
marker of neuronal activation. Bingham
et al. (23), using [11C]-3-O-methyl-D-
glucose PET, also showed an increase in
glucose tracer uptake in the prefrontal
cortex and anterior cingulate cortex dur-
ing hypoglycemia sufﬁcient to lower
global brain glucose content in subjects
with type 1 diabetes. Importantly, in the
latter study, cerebral metabolic rate for
glucose in the brain showed a relative rise
in aware subjects versus a relative fall in
unaware subjects. This is explained by
understanding that the tracer uptake and
metabolism are reﬂecting neuronal activ-
ity rather than insulin-stimulated glucose
uptake,withtheincreasedglucoseuptake
reﬂecting the involvement of cortical
brain regions in the generation or detec-
tion of symptoms. The anterior cingulate
cortex is an important brain region for
interoception, monitoring the body’s in-
ternal state, and is activated during in-
crease in sympathetic nervous system
activation. In the study by Bingham et al.,
the relative fall in the surrogate marker of
neuronal activation was associated with
failure of subjective awareness and not
with complete failure of hormonal stress
response.
A possible additional clinical signiﬁ-
cance of changes in the cortical response
to acute hypoglycemia was illustrated in a
recent analysis of 18-ﬂuoro-deoxy-
glucose uptake during hypoglycemia that
differentiated between the aware and
unaware (24). Engagement of appetite
control and reward-seeking networks
involvedinfoodseekingwasseen,butthe
responsesofthesenetworksweremeasur-
ably reduced in hypoglycemia unaware-
ness, with failure of amygdala and
orbifrontal cortex responses in particular
(Fig. 2). This suggests habituation of
higher behavioral responses to hypogly-
cemia, akin to stress desensitization, be-
ing a basis for unawareness. If conﬁrmed,
this would argue that the hypoglycemia-
unaware person is unaware both of the
hypoglycemia itself but also of its dangers
and unpleasantness. This may have im-
portant therapeutic implications.
Role of nonglucose substrates for
brain metabolism in hypoglycemia
unawareness
McCrimmon describes the evidence
showing the ability of nonglucose fuels,
particularlyketonesandlactate,tosustain
cerebral function during hypoglycemia,
and such information is used clinically in
treating some forms of epilepsy with ke-
togenic diets. Infusions of lactate and ke-
tones can sustain cortical function and
delay counterregulation during induced
hypoglycemia (25,26), and lactate infu-
sion reduced brain glucose uptake in a
neuroimaging study (27). Neuroimaging
data shows an upregulation of transport-
ers for monocarboxylic acid transporters
in hypoglycemia unawareness, the con-
cept being that because the neurons are
better able to use lactate during hypogly-
cemia, there is less neuronal drive for
counterregulation (28). As yet, neuroim-
aging data have compared diabetic sub-
jects with hypoglycemia unawareness
onlywithnondiabeticcontrolsubjects,so
theeffectofdiabetesaloneremainsuncer-
tain. If, however, the effect is associated
with reduced awareness and delayed
counterregulation, it is likely that there
are regional differences in its importance
across the brain because of the absence of
protection from severe hypoglycemia in
those who are hypoglycemia unaware.
Clinically, it is difﬁcult to see how these
data may be exploited. It is difﬁcult to
raise lactate levels with current agents
such as metformin in healthy subjects.
Alanine has also been shown to sup-
port some aspects of cognitive function
during hypoglycemia (29). It may appear
paradoxical that it also enhances the
counterregulatory responses to hypogly-
cemia, but this is restricted to the gluca-
gon responses, which are exaggerated
(30).Asimilarpotentiallybeneﬁcialeffect
is seen with oral amino acid ingestion.
The increase in blood glucose concentra-
tionfromabedtimesnackistransient(the
mainfunctionofthesnackbeingtocoun-
teract the tail action of the pre–evening
meal insulin), but including protein has
been suggested to enhance the defenses
against nocturnal hypoglycemia by pro-
viding amino acid. In contrast to alanine,
raising circulating fatty acids with in-
tralipid impacts only on the centrally
mediated hormonal responses to hypo-
glycemia with no effect on cognition, a
Figure 1—Epinephrine responses to controlled induced hypoglycemia before (‚) and after (E)
intensiﬁcation of diabetes control. The hatched area shows the response of a group of healthy
individuals who were slightly older than the diabetic subjects. Reprinted with permission from
Amiel et al. (14).
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therapeutically (31).
The risk of repeat hypoglycemia
Anecdotally, many patients experiencing
hypoglycemia will describe how episodes
tend to occur in clusters with great varia-
tion in the weekly frequency. This may of
course be caused by a subacute change in
insulin requirement related to other fac-
torssuchaslifestyleevents.Coxetal.(32)
have identiﬁed that greater changes in
glucose excursions are seen in the 48 h
before severe hypoglycemia in patients at
high risk and that a given episode of se-
vere hypoglycemia is preceded by a sig-
niﬁcant increase in the frequency of low
blood glucose measurements converted
into a low blood glucose index. The in-
creasedriskofasecondhypoglycemicep-
isode occurring within 24 h of a ﬁrst
episode is also likely to be enhanced by
thedownregulationofsymptomaticstress
responses induced by the ﬁrst episode.
George et al. (33) showed that only nor-
epinephrineresponseswerestillimpaired
48 h after an index hypoglycemia expo-
sure in type 1 diabetic patients, although
generalized reduction in response is seen
within 24 h. If, as some authorities sug-
gest, brain glycogen is important in the
defensesagainstseverehypoglycemiaand
it takes 24 h to restore them after hypo-
glycemia (34), this could be another con-
tributory factor.
Therapeutic strategies for improving
the defenses against hypoglycemia
Avoiding hypoglycemic experience.
Based on the evidence that exposure to
antecedent hypoglycemia induces and
maintains counterregulatory failure and
hypoglycemia unawareness and that res-
toration of counterregulatory responses
or awareness of early hypoglycemia is
achieved by hypoglycemia avoidance,
helping insulin users to minimize hypo-
glycemia exposure is an important focus
for current research. Education programs
that apparently focused exclusively on
this showed success in reducing hypogly-
cemia experience (35). However, a par-
ticularly impressive combination of
improved glycated hemoglobin and large
reduction in severe hypoglycemia rate
sustained over at 3 years was achieved
by the Du ¨sseldorf program and has since
been reproduced in other countries, in-
cluding the U.K., where it was translated
into Dose Adjustment for Normal Eating
(DAFNE) (36–38). These are 5 day in- or
outpatient programs delivered to small
groups of patients in which principles of
adult education are used to transfer skills
in insulin dose adjustment to the insulin
users. The courses share a common cur-
riculum delivered by trained educators,
and the best regularly undergo quality
control by peer review and are audited.
The insulin regimens are based on tested
algorithms for dose adjustment. Patients
are taught to use premeal and prebed
Figure 2—Regions of enhanced 18-ﬂuoro-deoxy-glucose uptake during hypoglycemia displayed on magnetic resonance imaging brain slices. A:
Relatively greater 18-ﬂuoro-deoxy-glucose uptake in amygdala, cerebellum, and brainstem in people with type 1 diabetes and hypoglycemia
awarenessthaninpeoplewithtype1diabetesandhypoglycemiaunawareness,consistentwithagreateranxietyandvigilanceresponseintheformer.
B: Relatively reduced 18-ﬂuoro-deoxy-glucose uptake in the right lateral orbitolfrontal cortex in people with good awareness of hypoglycemia
comparedwiththosewhoareunaware.Thereducedactivationofthisbrainregioninthosewithawarenesssuggestedbythesedataiscompatiblewith
the recognition of the unpleasantness or danger of the stimulus encouraging behavior to avoid hypoglycemia in future. This seems to be signiﬁcantly
less effective in those who are unaware. Reprinted with permission from Mason et al. (28).
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recting instantly for readings that are out
of target and also prospectively by reﬂect-
ing on the results of the previous few
days. The regimens are now not of them-
selves remarkable. They stress providing
meal insulin and basal insulin require-
ments independently, allowing ﬂexibility
of meal timing without loss of glycemic
control. Patients use carbohydrate count-
ing to determine meal doses, which are
described in ratios of insulin units re-
quired per unit carbohydrate consumed
at any meal. Much of the course is spent
perfecting the art of accurate carbohy-
drate counting using food models, food
plates, exercises, and real meals. Sessions
also discuss other factors that inﬂuence
diabetes control, provide algorithms for
adjusting for these factors, and explain
the rationale for the glucose targets cho-
sen. A recent audit of the U.K.’s DAFNE
program has shown that awareness of hy-
poglycemia can be restored to nearly half
the patients entering the program with
hypoglycemia unawareness at 1 year
post-training (38). Although a causal link
between reduced hypoglycemia experi-
enceandrestoredawarenessisnotproven
by these data, it is a plausible hypothesis.
Itisunlikelythatonesingleelementofthe
Du ¨sseldorf-basedprogramsisresponsible
for their success. The explicit splitting of
basal insulin replacement from meal re-
placementusingalgorithmsdevelopedby
experimentation, the support of the
small-groupeducationdeliveryanduseof
adult education techniques, and the op-
portunity to take time to learn how insu-
lin works with food all are likely to be
important. That a clinical audit of the
U.K.’s DAFNE program has recently
shown a beneﬁcial impact on depression
and anxiety in participants highlights the
complex nature of these interventions
(38).
Technology has helped as well. Meta-
analyses have failed to show a signiﬁcant
impact on diabetes control of the newer
insulin analogues in either type 1 or type
2 diabetes (39,40). However, in studies,
the ﬂatter action proﬁles of the long-
acting analogues, insulin glargine and de-
temir, and the highly peaked shorter
duration of action of the rapid-acting
analogues, humalog and insulin aspart,
consistently show less hypoglycemia,
especially at night. Clinical beneﬁts may
best be seen when they are properly used
in people at increased risk of hypoglyce-
mia problems. Continuous subcutaneous
insulin infusion has long been associated
in clinical observational studies with re-
duced frequency of severe hypoglycemia,
and this is supported by a series of ran-
domized controlled trials and a recent
meta-analysis (41). No one has speciﬁ-
cally shown that pump therapy per se has
been able to restore counterregulatory
failure, but it seems a likely association of
the improved experience of severe hypo-
glycemia.Mostrecently,theavailabilityof
real-time glucose monitoring, by which
the patient can observe the direction and
rate of change of plasma glucose in real
time using an electrode inserted into the
interstitial ﬂuid of the subcutaneous
space, has shown an ability to improve
glycated hemoglobin (with no increased
risk of hypoglycemia) in adults actively
practicingintensiﬁedinsulintherapy,pri-
marily with insulin infusion (42).
Theevidencesupportsthehypothesis
thatalltheabovestrategiesmaybedimin-
ishing the risk of severe hypoglycemia by
reducingthefrequencyofexposuretohy-
poglycemia of any kind. This would be
expected to improve hypoglycemia
awareness and counterregulatory re-
sponses. Although it is not clear what
constitutes the degree of hypoglycemia
experience that creates risk, in a study by
Cranston et al. (20) showing restoration
of both hormonal and symptom re-
sponses to experimentally induced hypo-
glycemia, the investigation was not
performed until the patients had demon-
strated a 3-week absence of exposure (on
conventional intermittent home blood
glucose monitoring) to plasma glucose
concentrations 3 mmol/l. Coinciden-
tally, 2.8–3 mmol/l is the arterialised
plasma glucose concentration in clamp-
induced experimental hypoglycemia at
which cognitive function ﬁrst becomes
detectable (as a deterioration in complex
reaction time) (43). Perhaps for these rea-
sons, the European Medicines Agency
(EMEA), responsible for the scientiﬁc
evaluation of applications for European
marketing authorization for medicinal
products, has chosen 3 mmol/l as its
deﬁnitionofhypoglycemiawhenexamin-
ing side effects of diabetes therapies (44).
This strategy is in contrast to the deﬁni-
tion favored by an American Diabetes As-
sociation workgroup of 4 mmol/l (45)
based on the evidence of activation of en-
dogenous counterregulatory responses
(increased glucagon and reduced endog-
enous insulin in health) and the ability of
experimental exposure of 3.9 mmol/l to
induce some defects in the counterregu-
latory response to subsequent hypoglyce-
mia. Because 3.9 mmol/l lies within the
physiologicalrangeandthepancreaticre-
sponses to hypoglycemia are impaired in
insulin-deﬁcient diabetes anyway (as far
as we know irretrievably), most clinical
guidelines use 3.5 mmol/l as the deﬁning
value of hypoglycemia requiring treat-
ment. This is important because deﬁning
a patient as experiencing signiﬁcant hy-
poglycemia has implications on their em-
ployment and leisure opportunities. In
particular, labeling a person as being hy-
poglycemiaunawarehasimportantimpli-
cationsforthoseindividuals,anddeﬁning
the glucose measurement below which
appearance of symptoms should be iden-
tiﬁed as having inadequate awareness is
fraught with pitfalls. Practically, and
giventheinaccuraciesofhomebloodglu-
cose measurement, the deﬁnition of hy-
poglycemia unawareness should not be
applied to people who are fully aware of
hypoglycemia at 3– 4 mmol/l or even
slightly less. The diagnosis is best made
clinically on the basis of the person’s
ability to recognize and successfully
treat episodes of hypoglycemia, almost
irrespective of the glucose concentra-
tion measured at the time.
Despite good evidence of restoration
of hypoglycemia awareness by hypogly-
cemia avoidance in research studies,
translating this into sustainable beneﬁt is
notuniversallysuccessful.Whereasabout
half of patients entering a DAFNE pro-
gram who have hypoglycemia unaware-
ness were hypoglycemia aware 1 year
later, about half still reported themselves
asbeinghypoglycemiaunaware(38).The
adaptation of the hedonic aspects of the
stress response to hypoglycemia in those
who were unaware seen in the neuroim-
aging studies described above is consis-
tent with the failure of any central signal
that hypoglycemia is unpleasant or dan-
gerous. This aspect of unawareness is
likelytoreducemotivationformakingbe-
havioral changes directed at hypoglyce-
mia avoidance. There are some early
clinic data to suggest that the ability to
change insulin regimens to avoid hypo-
glycemia is impaired in those who are hy-
poglycemia unaware (46). This may
explain the failure of purely educational
strategies to reduce problematic hypogly-
cemia in everyone. It is not known
whether the changes in the cortical re-
sponses to hypoglycemia are part of the
hypoglycemia-induced syndrome of un-
awareness and counterregulatory deﬁcit,
in which case they should be reversible,
orwhethertheyreﬂectapredispositionto
Hypoglycemia
1368 DIABETES CARE, VOLUME 32, NUMBER 8, AUGUST 2009respond to stress in this manner. The po-
tential for therapies directed at reversing
behavior patterns engendered by stress
desensitizationtohelppeoplewithintrac-
table hypoglycemia unawareness needs
urgent investigation.
Future directions for adjunctive thera-
pies to protect against severe hypogly-
cemia. Despite its lack of universal or
lasting success, avoidance of hypoglyce-
mia remains the most proven and effec-
tive strategy for reducing an individual’s
risk of severe hypoglycemia. Research
into improving our ability to avoid expo-
sure to subphysiological glucose concen-
trations remains a top priority. Current
therapeuticstrategiesshouldtargetavoid-
ance of exposure to low glucose concen-
trations and ways of achieving this
including ruling out or treating predis-
posing comorbidities, use of structured
patient education around insulin usage
and hypoglycemia avoidance as well as
use of pump therapy, glucose monitoring
strategies, and even for intractable
problems, consideration of replacement
of active islet tissue by transplantation.
However, complete protection against
hypoglycemia remains an elusive goal,
and research continues into other nong-
lycemic strategies that might give further
protection.
Based on an understanding of the
mechanisms of glucose sensing and nor-
mal counterregulation, people are begin-
ning to test the use of pharmacological
agents to defend against severe hypogly-
cemia. To counteract the observed defect
incatecholamineresponsestohypoglyce-
mia in those with long-standing type 1
diabetes,Cryerandcolleagues(47)exam-
ined the ability of the 2-adrenergic ago-
nist terbutaline to diminish the risk of
nocturnal hypoglycemia. The ﬁrst study
did reduce hypoglycemia rates but at the
expense of a generalized elevation of the
bloodglucosethroughthenight.Morere-
cently a lower dose has been tried that
achieved a better balance, but the effects
of elevating background catecholamine
action will require careful further testing.
McCrimmondescribesthreemolecular
pathwaysimplicatedinglucosesensingand
the initiation of counterregulation: the
AMP-activated protein kinase (AMPK); the
ATP-sensitive K
 (KATP) channels, and
the corticotropin-releasing hormone recep-
tor family (1). Some of these may be ame-
nable to pharmacological manipulation.
The methylxanthine derivatives an-
tagonize central adenosine A2 receptors
and increase intracellular cAMP, activat-
ing AMPK. They are associated with en-
hanced neuronal activation, alertness,
and catecholamine secretion; drive the
hepatic glucose response to adrenaline
and glucagon; induce vasopressor re-
sponses; and reduce cerebral blood ﬂow.
Their cerebral effects, enhanced neuronal
activation, and reduced cerebral blood
ﬂow are the reverse of the effects of hypo-
glycemia. Nevertheless, both caffeine and
theophyllinehavebeenshowntoenhance
symptomatic and hormonal responses to
hypoglycemia, effects which some have
suggestedmayrelatetoagreaterdegreeof
neuroglycopenia at any given blood glu-
cose concentration by limiting the in-
crease in cerebral blood ﬂow that
hypoglycemia should elicit. Both agents
have been shown to increase counter-
regulatory responses. In the case of the-
ophylline, 2 weeks of therapy resulted in
loss of the ability of the drug to enhance
the catecholamine responses to hypo-
glycemia but preservation of the en-
hancement of vascular, sweating, and
symptomatic responses (48). It is not,
however,knownwhetherthetherapywas
associated with changes in glycemic con-
trol as a contributory mechanism. In the
case of caffeine, again some of its appar-
ently beneﬁcial effects on subjective
awareness of hypoglycemia are retained
(49), but this may be at least in part be-
causeitreducesthefrequencyofhypogly-
cemia, as shown by continuous glucose
monitoring (50). Caffeine may also exac-
erbate aspects of cortical function deﬁcits
in susceptible individuals while helping
preserve others during hypoglycemia
(51). Other drugs that activate AMPK di-
rectly or activate adenylate cyclase may
alsobeworthinvestigating.Theseinclude
metformin and prostacyclin.
The complexity of manipulation of the
molecularmechanismsofglucosesensingis
illustratedbyexaminingattemptstoexploit
the involvement of the KATP channels in
neuronal glucose sensing to enhance coun-
terregulatory responses. Intracerebrovascu-
lar administration of the KATP channel
opener diazoxide increases counterregula-
tory hormone responses, and sulfonylurea
reduces them (1). In a human study, how-
ever, a single dose of the sulfonylurea glib-
enclamide had equivocal effect on normal
glucose counterregulatory hormone release
but diminished the cognitive dysfunction
seen with the hypoglycemia, compatible
with the presence of sulfonylurea receptors
inthecortex(52).Furtherworkneedstobe
done in this area, including apparently par-
adoxical studies of the effects of both ATP
channel openers such as diazoxide-like
agents and closers such as glibenclamide.
A possible ﬁnal common pathway
throughwhichglucosesensingmayaffect
counterregulatory stress responses is
through manipulating brain concentra-
tions of the inhibitory neurotransmitter
-aminobutyric acid (GABA), disinhibit-
ing the stress responses. As described by
McCrimmon in an animal study, localized
blocade of -aminobutyric acid–recep-
tor-A1receptorsintheglucose-sensingven-
tromedial hypothalamus can enhance
glucagon and epinephrine responses to hy-
poglycemia,althoughgrowthhormoneand
cortisol responses were unaffected (1). In a
single-dose healthy volunteer study,
modaﬁnil, which diminishes brain GABA
levels by noradrenergic stimulation of sero-
tonergic neurons, enhanced heart rate re-
sponses and symptom scores during
hypoglycemia and supported some aspects
of cognitive function (53). It had no effect
on catecholamine or glucagon responses.
Modaﬁnil is used to support higher brain
functioninnarcolepsy,anditsactionsinthe
hypoglycemia study may be exclusively
cortical. In contrast, selective serotonin re-
uptake inhibitors, by blocking also neuro-
nal norepinephrine transport, can enhance
sympathetic outﬂow activity, and in exper-
imental human studies, high-dose ﬂuox-
etine for 6 weeks prior to induced
hypoglycemia enhanced epinephrine and
muscle sympathetic nerve activity in hypo-
glycemia but had no effect on subjective
awareness(54).Theclinicalbeneﬁtofthese
observations is uncertain. As yet, there has
been no clinical translation of the emerging
data on the corticotropin-releasing factor
receptor involvement in glucose sensing.
Further implications of the research
into glucose sensing and impact on
other pharmacological therapies in di-
abetes. The investigation of the molecu-
lar mechanisms for glucose sensing have
implications for drug development in di-
abetes apart from the protection from hy-
poglycemia. In the search for better
therapies for hyperglycemia, agents that
are likely to affect glucose sensing are ac-
tively being explored. Current initiatives
include the development of activators of
glucokinase, which may be expected to
lower plasma glucose by enhancement of
liver glucose uptake and by enhancement
of insulin secretion (55). If the glucoki-
nase activators have access to the central
nervoussystem,theymayalsoalterhypo-
glycemia sensing. Similarly, sodium-
glucose transporters are a target for
therapeutic blood glucose lowering by
Amiel
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(56). Sodium-glucose cotransporters
(SGLTs)arefoundingutandinthebrain,
including the ventromedial hypothala-
mus (VMH) (1). Phlorizin, a nonselective
inhibitor of SGLTs too toxic for human
use, inhibits glucose-induced excitation
of ventromedial hypothalamus neurons;
therefore, SGLT inhibition may paradox-
ically stimulate a stress response that
mightbeexpectedtoexaggeratethecoun-
terregulatory hormone response, al-
though this has not been tested.
SUMMARY AND
CONCLUSIONS — Hypoglycemia
remainsasigniﬁcantlimitationtooptimal
treatment of diabetes with insulin and in-
sulin secretagogues. Current research
into the physiology of hypoglycemic
counterregulation has helped us under-
stand how to reduce risk of severe hypo-
glycemia, but much remains to be
understood and exploited. In those with
type 1 diabetes, risk for hypoglycemia is
increased by the completeness of the in-
sulin deﬁciency as well as the associated
failure of glucagon responses to hypogly-
cemia and additional failure of other
counterregulatory mechanisms created at
leastinpartbyrepeatedexposuretomod-
est hypoglycemia itself. For those with
long duration type 2 diabetes, hypoglyce-
mia risk also increases with increasing in-
sulin deﬁciency. Teaching patients to use
insulin ﬂexibly around changes in diet,
exercise, alcohol ingestion, and other fac-
tors inﬂuencing insulin requirements and
sensitivity can improve glycemic control
whilereducinghypoglycemiarisk.There-
after,increasinguseoftechnologyinboth
insulin delivery and, more recently, glu-
cose sensing may be helpful. For the pa-
tient with truly intractable hypoglycemia,
replacement of functional islet tissue by
isletororgantransplantationisalsoacur-
rent therapeutic option. For the future,
research into agents that may inﬂuence
glucose sensing or cerebral and periph-
eral metabolism may offer new ways of
enhancingdefensesagainsthypoglycemia
in the delivery of truly good glycemic
control.
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